LSBIO acquires Absolute Antibody

LSBio, a provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody, its sister company Kerafast.

LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The company has built a catalogue of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals, and its acquisition of Absolute Antibody and Kerafast further expands its product portfolio by adding a range of reagents and antibody services.

Absolute Antibody specialises in recombinant antibody technology, offering antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats. In 2018, Absolute Antibody merged with Kerafast, a Boston-based company that facilitates access to laboratory-made reagents, to further the availability of recombinant antibodies. The new acquisition combines a strong recombinant antibody portfolio with LSBio’s expertise in application-specific validation to make sequence-defined, reproducible antibodies more widely available for IHC and other key research applications.

“We are very excited to add Absolute Antibody and Kerafast into the LSBio family of companies,” said Dr Heather Holemon, CEO of LSBio. “It provides an opportunity to offer more to our customers by adding their recombinant antibody production and engineering capabilities as well as their highly complementary product portfolio. This transaction aligns with our goal of providing researchers access to what they are asking for as far as superior consistency and better validation.”

“We are delighted to be joining forces with the LSBio team,” said Dr. Nicholas Hutchings, founder and CEO of Absolute Antibody. “Absolute Antibody was founded with a vision to make engineered recombinant antibodies accessible to all, and we have grown rapidly as the demand for recombinant antibody technology has increased. That vision remains and working with LSBio enables us to continue growing both the recombinant antibody catalogue and our custom services, while still delivering the highest level of product quality and customer satisfaction.”

 

 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free